This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MorphoSys Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

MorphoSys şirketinin toplam hissedar öz sermayesi €-261.7M ve toplam borcu €1.7B olup, bu da borç-öz sermaye oranını -658% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla €1.8B ve €2.1B dir.

Anahtar bilgiler

-658.0%

Borç/özkaynak oranı

€1.72b

Borç

Faiz karşılama oranı	n/a
Nakit	€630.77m
Eşitlik	-€261.67m
Toplam yükümlülükler	€2.09b
Toplam varlıklar	€1.83b

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: MOR negatif hissedar özkaynağı var; bu, kısa vadeli varlıkların kısa vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Uzun Vadeli Yükümlülükler: MOR şirketinin negatif özkaynağı bulunmaktadır; bu, kısa vadeli varlıkların uzun vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: MOR negatif hissedar özkaynağı var ki bu yüksek borç seviyesinden daha ciddi bir durumdur.

Borcun Azaltılması: MOR 'in negatif özkaynağı var, dolayısıyla borcunun zaman içinde azalıp azalmadığını kontrol etmemize gerek yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: MOR şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: MOR, serbest nakit akışı her yıl % 35.7 oranında tarihi oranda azalmaya devam ederse 3 yıldan fazla bir süre yeterli nakit akışına sahip olur

This company listing is no longer active

MorphoSys Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and Nasdaq Global Market

MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market

Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys

Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys

Recent updates

MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and Nasdaq Global Market

MorphoSys AG, Annual General Meeting, Aug 27, 2024

MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market

MorphoSys AG to Report Q2, 2024 Results on Aug 29, 2024

MorphoSys AG(XTRA:MOR) dropped from Germany MDAX Index (Performance)

MorphoSys AG(XTRA:MOR) dropped from Germany TECDAX (Total Return) Index

MorphoSys AG Appoints Arkadius Pichota as Chief Executive Officer

MorphoSys AG Announces Board Changes

Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys

Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys

New major risk - Negative shareholders equity

New major risk - Financial position

First quarter 2024 earnings released: €8.27 loss per share (vs €1.30 loss in 1Q 2023)

Full year 2023 earnings released: €5.53 loss per share (vs €4.42 loss in FY 2022)

Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.

Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.

MorphoSys AG Provides Sales Guidance for the Financial Year 2024

Investor sentiment improves as stock rises 20%

Investor sentiment deteriorates as stock falls 15%

New minor risk - Shareholder dilution

MorphoSys AG to Report First Half, 2024 Results on Aug 07, 2024

MorphoSys AG has filed a Follow-on Equity Offering in the amount of €102.69582 million.

MorphoSys AG to Report Fiscal Year 2023 Results on Mar 13, 2024

MorphoSys AG’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study

Investor sentiment deteriorates as stock falls 43%

MorphoSys AG Announces Strong Topline Results from the Phase 3 MANIFEST-2 Study Investigating Pelabresib

New major risk - Financial position

Third quarter 2023 earnings released: €3.50 loss per share (vs €3.60 loss in 3Q 2022)

MorphoSys AG to Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting

Investor sentiment improves as stock rises 18%

Morphosys AG Provides Earnings Guidance for the Year 2023

Investor sentiment deteriorates as stock falls 15%

Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH from founders, High-Tech Gründerfonds, the Swiss Occident Group AG and MorphoSys AG (XTRA:MOR).

MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: €2.16 loss per share (vs €6.88 loss in 2Q 2022)

MorphoSys AG Provides Earnings Guidance for the Year 2023

Morphosys Ag Provides Sales Guidance for the Financial Year 2023

First quarter 2023 earnings released: €1.30 loss per share (vs €3.59 loss in 1Q 2022)

Full year 2022 earnings released: €4.42 loss per share (vs €15.40 loss in FY 2021)

MorphoSys AG Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024

MorphoSys AG Announces Sung Lee, Chief Financial Officer Decided to Leave

Morphosys Presents New Longer-Term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity At Ash 2022

MorphoSys AG to Report Q3, 2023 Results on Nov 15, 2023

Third quarter 2022 earnings released: €3.60 loss per share (vs €3.30 loss in 3Q 2021)

MorphoSys AG Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209)

Morphosys Ag Revises Monjuvi U.S. Net Product Sales Guidance for the Full Year of 2022

MorphoSys AG Announces Executive Changes

Second quarter 2022 earnings released: €6.88 loss per share (vs €0.64 profit in 2Q 2021)

Morphosys Ag Updates Monjuvi U.S. Net Product Sales Guidance for the Year 2022

MorphoSys AG Confirms Financial Guidance for the Year 2022

MorphoSys AG Announces Supervisory Board Changes

First quarter 2022 earnings released: €3.59 loss per share (vs €1.27 loss in 1Q 2021)

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

MorphoSys Presents Latest Data from the Phase 2 Manifest Study Evaluating the Potential of Pelabresib in the Treatment of Myelofibrosis

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin